Normafenac (Cefuroxime Sodium)

Cefuroxime sodium, the active ingredient in Normafenac, is a cephalosporin presented as an injectable for intramuscular and intravenous use. It treats a range of bacterial infections in adult and pediatric patients as determined by a healthcare professional.

GNH USA supplies Normafenac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Cefuroxime sodium is a broad‑spectrum cephalosporin antibiotic used to treat bacterial infections.

- Respiratory tract infections: effective against community‑acquired pneumonia and acute bronchitis. - Skin and soft‑tissue infections: clears cellulitis, wound infections and erysipelas. - Urinary tract infections: resolves uncomplicated cystitis and pyelonephritis.

Cefuroxime sodium may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Injection site pain - Diarrhea - Nausea - Vomiting - Rash

Serious or Rare Side Effects: - Anaphylaxis or severe hypersensitivity reactions - Neutropenia or agranulocytosis - Clostridioides difficile‑associated colitis

Before initiating therapy, clinicians should consider several safety measures.

- Allergy assessment: confirm no known hypersensitivity to cephalosporins or penicillins. - Renal function: adjust dose in patients with severe renal impairment. - Pregnancy: use only when the potential benefit justifies the potential risk to the fetus. - Concomitant antibiotics: avoid overlapping spectrum without specialist guidance. - Monitoring: watch for signs of superinfection or C. difficile colitis. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Cefuroxime sodium can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Probenecid: may raise cefuroxime plasma concentrations and increase toxicity. - Live bacterial vaccines: concurrent use can diminish vaccine effectiveness.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR, requiring closer coagulation monitoring. - Aminoglycosides: additive risk of nephrotoxicity. - Diuretics: may affect renal clearance of cefuroxime, necessitating dose review.